The HeartLight EAS incorporates an endoscope to provide physicians to see within the heart, visually direct the application of laser energy to achieve pulmonary vein isolation.

The device features an adjustable balloon catheter for improved contact with the pulmonary vein (PV) ostium and utilizes laser energy for ablation.

Recent data has demonstrated that approximately 86% of PVs remained persistently isolated after three months following a single procedure with HeartLight EAS, with 65% of patients achieving durable freedom from AF.

The HeartLight EAS received CE Mark in 2009 for the treatment of atrial fibrillation, and is commercially available at leading institutions throughout Europe.

It is investigational in the US, with a pivotal study expected to commence in 2011.

CardioFocus president and CEO Stephen Sagon said they are encouraged by the adoption of the technology by numerous cardiologist and expect to broaden the use of the system in Europe as a new treatment option for AF patients.